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A patient preference study that evaluated fluticasone furoate
and mometasone furoate nasal sprays for allergic rhinitis
Anahi Yanez, M.D.,1 Alex Dimitroff, B.Pharm.,2 Peter Bremner, M.D.,3 Chae-Seo Rhee, M.D., Ph.D.,4
Graham Luscombe, Ph.D.,5 Barbara A. Prillaman, M.S., M.A.,6 and Neil Johnson, B.Sc.5
ABSTRACT
Background: Corticosteroid nasal sprays are the mainstay of treatment for allergic rhinitis. These sprays have sensory
attributes such as scent and/or odor, taste and aftertaste, and run down the throat and/or the nose, which, when unpleasant,
can affect patient preference for, and compliance with, treatment.
Objective: This study examined patient preference for fluticasone furoate nasal spray (FFNS) or mometasone furoate nasal
spray (MFNS) based on their sensory attributes after administration in patients with allergic rhinitis.
Methods: This was a multicenter, randomized, double-blind, cross-over study. Patient preferences were determined by using
three questionnaires (Overall Preference, Immediate Attributes, and Delayed Attributes).
Results: Overall, 56% of patients stated a preference for FFNS versus 32% for MFNS (p  0.001); the remaining 12%
stated no preference. More patients stated a preference for FFNS versus MFNS for the attributes of “less drip down the throat”
(p 0.001), “less run out of the nose” (p 0.05), “more soothing” (p 0.05), and “less irritating” (p 0.001). More patients
responded in favor of FFNS versus MFNS for the immediate attributes, “run down the throat” (p  0.001), and “run out of
the nose” (p  0.001), and, in the delayed attributes, “run down the throat” (p  0.001), “run out of the nose” (p  0.01),
“presence of aftertaste” (p  0.01), and “no nasal irritation” (p  0.001).
Conclusion: Patients with allergic rhinitis preferred FFNS versus MFNS overall and based on a number of individual
attributes, including “less drip down the throat,” “less run out of the nose,” and “less irritating.” Greater preference may
improve patient adherence and thereby improve symptom management of the patient’s allergic rhinitis.
(Allergy Rhinol 7:e183–e192, 2016; doi: 10.2500/ar.2016.7.0185)
Allergic rhinitis is a global health problem that af-fects 500 million people worldwide.1 The
symptoms of allergic rhinitis include nasal congestion;
cough; snoring; postnasal drip; reduced sense of
smell; headache; and red, itching eyes, with symp-
toms being evident for 4 months of the year in
approximately half of the patients. These symptoms
can also affect patients’ quality of life by reducing
sleep quality, increasing irritability and depression,
and impacting social activities.2 Corticosteroid nasal
sprays are the therapeutic mainstay for patients with
allergic rhinitis.3,4 However, these nasal sprays have
sensory attributes, such as scent and/or odor, taste,
and aftertaste. Patients’ perceptions of these attri-
butes may influence their preference for, and satis-
faction with, treatment.5,6 Furthermore, perceptions
of nasal spray attributes have been shown to influ-
ence treatment compliance,6 with unpleasant sen-
sory attributes leading to a reduction in adherence,
which, in turn, can lead to poor symptom manage-
ment.2,7,8
Results from clinical trials of patients with allergic
rhinitis show that clinical efficacy and tolerability are
similar for different corticosteroid nasal sprays.9–11
However, previous studies of corticosteroid nasal
sprays to determine the importance of different at-
tributes in patient preference showed that patients
can differentiate between the treatments based on
attribute profiles.6,11–17 These findings highlight the
potential role of treatment attributes in adherence
and, consequently, in clinical outcomes. Fluticasone
furoate (FF) and mometasone furoate (MF) are cor-
ticosteroids that are both delivered by using nasal
sprays, but with different actuation systems. The FF
nasal spray (FFNS) (Avamys GlaxoSmithKline, Ux-
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bridge, UK [U.S. trade name, Veramyst]18) is side
actuated, whereas the MF nasal spray (MFNS) (Na-
sonex Merck Sharp & Dohme Limited, Hoddesdon,
UK19) is top actuated. Furthermore, the FFNS deliv-
ery system has a shorter nozzle and lower volume
per actuation than other nasal spray devices, which
may result in less postnasal runoff.20 The FFNS and
MFNS were optimized to reduce strong scent and/or
odor and irritation because these are characteristics
reported as being unfavorable to patients.13,20
To date, there have been single-dose patient pref-
erence studies between FFNS and the fluticasone
propionate nasal spray (FPNS) (Flixonase Glaxo-
SmithKline [U.S. trade name, Flonase]21)14 and be-
tween MFNS and FPNS.13 The only previous direct
comparison of patient preferences for FF or MF in-
volved administering each nasal spray for 2 weeks.22
In the current single-dose study (NCT02397915; Glaxo-
SmithKline (GSK) study no. 201474) of patients with
allergic rhinitis, we examined patient preferences for
the FF and MF aqueous corticosteroid nasal sprays,
based on the sensory attributes of each. In addition, we
evaluated whether the differences between the nasal
sprays (e.g., actuation system, volume per actuation,
fineness of spray, nozzle length) were reflected in the
patient-assessed attribute ratings.
METHODS
Patients
The patients were men and women, 18–65 years of
age, with either seasonal or perennial allergic rhinitis
confirmed by a positive allergen skin test result
within 12 months of study treatment. Women who
were pregnant or breast-feeding were excluded, as
were patients with an infection or structural abnor-
mality of the respiratory system. In addition, pa-
tients who used an intranasal corticosteroid within 4
weeks of study participation, other intranasal medi-
cations within 1 week of study participation, medi-
cations that could disturb taste or smell, significant
inhibitors of the cytochrome P450 subfamily CYP3A4
within 4 weeks of study participation, or who had a
history of sensitivity to the study procedures or
drugs were excluded. Use of perfume or strong-
smelling cosmetic products, oral rinse or similar
products, tobacco, or inhaled or oral nicotine-con-
taining products (within 12 hours before the start of
dosing) were also causes for exclusion from enroll-
ment.
Study Drugs
FFNS suspension delivered 27.5 g FF per actuation
with excipients: glucose anhydrous, dispersible cellu-
lose, polysorbate 80, benzalkonium chloride, disodium
edetate, and purified water. MFNS suspension deliv-
ered 50 g per actuation with excipients: benzalko-
nium chloride, dispersible cellulose (microcrystalline
cellulose and carmellose sodium), glycerol, sodium
citrate, citric acid monohydrate, polysorbate 80, and
purified water.
Study Design and Objectives
This was a multicenter, randomized, double-blind,
single-dose, crossover patient preference study (Fig. 1).
The study was carried out at 12 sites across four coun-
tries: Argentina (4 sites), Australia (3), Russia (2), and
South Korea (3). Patients with allergic rhinitis were
randomized 1:1 (by using a computer-generated code)
to one of two treatment sequences: either a single dose
each of MFNS followed by FFNS, or a single dose each
of FFNS followed by MFNS. The FFNS (110 g) was
administered as two sprays of 27.5 g FF per spray in
each nostril, and the MFNS (200 g) was administered
as two sprays of 50 g MF per spray in each nostril.
The primary objective was to determine overall patient
preference for FFNS or MFNS by using the Overall
Preference Questionnaire (OPQ). Secondary objectives
were to determine the patient preference for individual
attributes of FFNS or MFNS by using the OPQ and to
compare the patient ratings for individual attributes of
FFNS and MFNS by using the Immediate Attributes
Questionnaire (IAQ) and the Delayed Attributes Ques-
tionnaire (DAQ).
SCREENING PERIOD 1 PERIOD 2 FOLLOW-UP
24h
and
96h
TNSS
Washout
Immediate
Aributes
Quesonnaire
Immediate
Aributes
Quesonnaire
Washout
Delayed
Aributes
Quesonnaire
Delayed
Aributes
Quesonnaire
Preference
Quesonnaire
30 min
Treatment
FF or MF
Treatment
FF or MF
Figure 1. Study schema. TNSS  Total Nasal
Symptom Severity; FF  fluticasone furoate;
MF  mometasone furoate.
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Study Procedures
The patients were screened for eligibility, random-
ized, and administered all treatments in one day.
During screening, a linguistically validated instanta-
neous Total Nasal Symptom Severity (TNSS) ques-
tionnaire was completed by the patient to assess the
potential impact of the degree of rhinitis symptom-
atology at baseline on the patient’s assessment of
nasal spray attributes. The TNSS assessed the symp-
toms: nasal congestion, rhinorrhea, sneezing, and
pruritus. Each of the four symptoms was scored
individually on a four-point scale (0, none; 1, mild; 2,
moderate; 3, severe), and the scores were added to
obtain the TNSS score (see Supplemental Appendix 1
for full details). The patients were blindfolded, and
treatment with FFNS or MFNS was administered by
an independent person who was not involved with
any protocol-related assessments. The second study
treatment was administered 30 minutes after the
first treatment. Washout procedures were performed
to cleanse the mouth and nasal passage 10
minutes before the first and second nasal spray treat-
ments by using a method established in previous
studies.13,14,17
Study Questionnaires and Assessments
Two sets of attribute questionnaires were completed
after each medication (FFNS or MFNS); immediate
(immediately after dosing) and delayed (2 minutes
after dosing). The OPQ was completed immediately
after the DAQ for the second treatment. All question-
naires were linguistically validated and provided in
the primary language of the country where the patient
was enrolled. The IAQ, DAQ, and OPQ have been used
previously.13,14 The OPQ required the patient to state
his or her overall preference for treatment with FFNS
or MFNS and for each attribute (Supplemental Table
1); a “no preference” response was available and was
included in the statistical analyses. The IAQ and DAQ
each used a seven-point Likert scale, which ranged
from 0 to 6, to rate individual attributes (Supplemental
Tables 2 and 3; Supplemental Appendix 1). Safety in-
formation was collected by recording adverse events
(AE) while at the study site and during follow-up
telephone contact with the patients. Follow-up safety
assessments took place 24  4 hours and 96  4 hours
after treatments.
Statistical Analysis
Sample size was based on an overall preference for
FFNS instead of MFNS in 60% of the patients (as ob-
served as the preference for FFNS instead of FPNS in the
study by Meltzer et al.14) and a significance level of 0.05.
By using a two-sided, one-sample 2 test, a sample size of
263 patients provided 90% power to show the expected
difference in proportions. Approximately 300 patients
were randomized to ensure availability of data from at
least 263 evaluable patients. The per-protocol population
included all patients who were randomized and who
received FFNS and MFNS, did not have a significant
deviation from the protocol, and completed both treat-
ment periods and the associated questionnaires. The
safety population included all patients who were ran-
domized. Overall and individual preference questions
were analyzed by using a Cochran-Mantel-Haenszel test
stratified by country and rhinitis symptomatology. Im-
mediate and delayed attribute ratings were assessed sep-
arately in terms of the difference between treatments in
mean rating scores. This assessment used analysis of
variance mixed models with attribute rating as the re-
Table 1 Baseline demographic data and rhinitis
assessments (total population N  300)*
Variable
Sex, no. (%)
Women 185 (62)
Men 115 (38)
Race, no. (%)
White 219 (73)
Asian 75 (25)
Other 6 (2)
Median age (range), y 40 (17–65)
Duration of rhinitis, no. (%)
1 y 0
1 to 5 y 20 (7)
5 to 10 y 50 (17)
10 y 230 (77)
History of seasonal allergic rhinitis,
no. (%)
Yes 193 (64)
No 107 (36)
History of perennial allergic rhinitis,
no. (%)
Yes 161 (54)
No 139 (46)
History of smoking, no. (%)
Never 232 (77)
Current 23 (8)
Former 45 (15)
TNSS score, mean  SD 3.6  2.9
Asymptomatic (TNSS score 3),
no. (%)
162 (54)
Symptomatic (TNSS score 4),
no. (%)
138 (46)
TNSS  Total Nasal Symptom Severity; SD  standard
deviation.
*Total population comprises all patients, including those
who did not pass the screening process.
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sponse variable; subject as the random effect; and coun-
try, treatment, period, baseline rhinitis symptomatology
subgroup, and treatment sequence as main effects. The
set of attribute preferences and each of the two sets of
individual attributes ratings (immediate and delayed)
were adjusted for multiple comparisons by using the
Hochberg method.23
Ethics and Good Clinical Practice
The study was conducted in accordance with the
International Conference on Harmonisation Good
Clinical Practice requirements and the ethical princi-
ples outlined in the Declaration of Helsinki. Ethical
approvals were obtained from an institutional review
board for each participating site. All patients provided
written informed consent.
RESULTS
Patient Baseline Demographics and Rhinitis
Assessments
Overall, 300 patients were recruited; a total of 276 pa-
tients completed the study and were included in the
per-protocol population. Two patients withdrew from
the study prematurely, which resulted in 298 patients
available for the safety population analyses. In the safety
population, 185 patients (62%) were women and the ma-
jority (73%) were white (Table 1). The duration of rhinitis
was 10 years in 230 patients (77%), with 193 patients
(64%) reporting seasonal allergic rhinitis and 161 patients
(54%) reporting perennial allergic rhinitis. The mean
(standard deviation) TNSS score was 3.6  2.9; 162 pa-
tients (54%) were asymptomatic (TNSS score, 3), and
138 patients (46%) were symptomatic (TNSS score, 4).
Patient Preferences, Overall and By Attribute
There was a significant (p  0.001) difference in
patients’ stated preference for FFNS or MFNS. The
majority of patients (56% [n  155]) stated a preference
for FFNS (110 g), 32% (n  87) preferred MFNS (200
g), and 12% (n  34) stated no preference (Fig. 2).
When preference for specific attributes was exam-
ined, significantly more patients preferred FFNS
than MFNS for “less drip down the throat” (p 
0.001), “less run out of the nose” (p  0.05), “more
soothing” (p  0.05), and “less irritating” (p  0.001)
(Fig. 2). Both the symptomatic (TNSS score, 4) and
asymptomatic (TNSS score, 3) subgroups preferred
FFNS to MFNS, with a trend for a larger proportion
of patients who preferred FFNS in the asymptomatic
group (not tested due to a lack of statistical power in
the subgroups).
Patient Ratings for Individual Attributes
When immediate attributes were assessed (Figs. 3 and
4) (Likert scale), there was a significant difference be-
tween treatments in the mean rating scores of immediate
“run down the throat” (p  0.001) and immediate “run
out of the nose” (p 0.001) (Fig. 4). Other mean attribute
rating scores did not differ significantly between the
groups. Examination of the ratings of delayed attributes
(Figs. 5 and 6) (Likert scale) showed statistically signifi-
cant differences in the rating scores between the FFNS
and MFNS treatments to the questions: “Did medicine
run down the throat?” (p 0.001), “Didmedicine run out
of the nose?” (p  0.01), “Did product have an after-
taste?” (p  0.01), “Did product cause nasal irritation?”
(p 0.001), and “How bothersome was nasal irritation?”
Figure 2. Overall and specific at-
tribute preference for fluticasone
furoate nasal spray (FFNS) and
mometasone furoate nasal spray
(MFNS) (per-protocol population).
*p  0.05, ***p  0.001.
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(p  0.01) (Fig. 6). Other mean attribute rating scores for
the questions: “How satisfied with the product?” and
“How likely to comply if prescribed?” did not differ
significantly between the treatment groups (data not
shown).
Treatment-Order Effects
The proportion of patients who preferred FFNS to
MFNS overall was greater in the group that was ad-
ministered FFNS first (70% FFNS versus 22% MFNS)
Figure 3. IAQ ratings for scent and/or odor, and taste (per-protocol population*). *(A) and (D) Show the per-protocol population; (B), (C),
(E) are subsets of the per-protocol population. (B) Contains responses from patients who responded other than “None” in (A). (C) Contains
responses from patients who responded “None” in (A). (E) Contains responses from patients who responded other than “None” in (D).
IAQ  Immediate Attributes Questionnaire; FFNS  fluticasone furoate nasal spray; MFNS  mometasone furoate nasal spray.
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compared with the total per-protocol population (56%
FFNS versus 32% MFNS). When MFNS was adminis-
tered first, the overall proportions of patients who
preferred FFNS or MFNS were 43 and 41%, respec-
tively.
AEs
Overall, five patients (2% of the safety population)
reported AEs related to receiving FFNS treatment and
13 patients (4%) reported AEs related to receiving
MFNS (Table 2). The AE profile was generally similar
between the treatment arms. No new safety signals
were observed in this study. There were no serious
AEs.
DISCUSSION
We presented a patient preference study of single
treatments of the nasal corticosteroid sprays FFNS and
MFNS for allergic rhinitis. The treatments were com-
pared based on sensory attributes and assessed by
using patient questionnaires. Results from the OPQ
showed that patients reported an overall preference for
FFNS (110 g) instead of MFNS (200 g). Both patients
who were symptomatic and patients who were asymp-
tomatic preferred FFNS to MFNS, with a trend for a
greater difference in preference in the asymptomatic
group. However, this trend could not be tested statis-
tically because there was insufficient statistical power
in the individual subgroups. Patients preferred FFNS
instead of MFNS based on the individual attributes of
“less run down the throat,” “less run out of the nose,”
“more soothing,” and “less irritating.” These prefer-
ences may relate to the lower spray volume of aqueous
solution used in FFNS (total volume, 200 L), com-
pared with MFNS (total volume, 400 L) as well as
differences in nozzle lengths and the fineness and dis-
persal of the spray. There was little difference in pref-
erence for the treatments based on taste- or odor-re-
lated attributes, which may be because both FFNS and
MFNS were developed to minimize odor, although
Figure 4. IAQ ratings for running down the throat, running out of the nose, soothing feeling, and urgency to sneeze (per-protocol
population). IAQ  Immediate Attributes Questionnaire; FFNS  fluticasone furoate nasal spray; MFNS  mometasone furoate nasal
spray.
e188 Winter 2016, Vol. 7, No. 4
Delivered by Ingenta to: The University of Notre Dame Australia  IP: 203.19.81.250 On: Wed, 06 Sep 2017 04:50:56
Copyright (c) Oceanside Publications, Inc. All rights reserved.
For permission to copy go to https://www.oceansidepubl.com/permission.htm
there was a preference for FFNS based on aftertaste. It
should be noted that, although only 12% of the patients
indicated that they had no overall preference for FFNS
instead of MFNS, between 26 and 72% of the patients
expressed no preference for either FFNS or MFNS
based on individual attributes.
Compared with the total per-protocol population, a
greater proportion of patients preferred FFNS when it
Figure 5. DAQ ratings for scent and/or odor, and taste (per-protocol population*). *(A) and (D) Show the per-protocol population;
(B), (C), and (E) are subsets of the per-protocol population. (B) Contains responses from patients who responded other than “None”
in (A). (C) Contains responses from patients who responded “None” in (A). (E) Contains responses from patients who responded other
than “None” in (D). DAQ  Delayed Attributes Questionnaire; FFNS  fluticasone furoate nasal spray; MFNS  mometasone
furoate nasal spray.
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was given first (although it was not possible to test this
statistically in this study). However, patients were ran-
domly assigned to one of two treatment sequences
(FFNS then MFNS or MFNS then FFNS), and the sta-
tistical analysis of variance models did take account of
the treatment order. The difference in spray volume
may also contribute to the possible association between
treatment order and preference. Because the MFNS has
a larger volume, it may linger longer despite the wash-
out and may lead to blunting of the perception of the
Figure 6. DAQ ratings for running down the throat, soothing feeling, and nasal irritation (per-protocol population*). *(A–D) Show the
per-protocol population; (E) is a subset of the per-protocol population. (E) Contains responses only from patients who responded other than
“None” in (D). DAQ  Delayed Attributes Questionnaire; FFNS  fluticasone furoate nasal spray; MFNS  mometasone furoate nasal
spray.
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second spray (FFNS). This finding was consistent with
the study by Shah et al.,16 which showed that patients
randomized to receive budesonide aqueous nasal
spray before FPNS had a stronger preference for
budesonide aqueous nasal spray than those who re-
ceived budesonide aqueous nasal spray second.
Results of the current study complement previous
findings. A study that used a similar methodology to
that described here reported that patients preferred
MFNS (53%) instead of FPNS (34%).13 In a further
single-dose study by the same group, patients pre-
ferred FFNS (60%) instead of FPNS (33%).14 A study in
Japan also investigated patient preference for FFNS or
MFNS by using a crossover design, although over a
longer 2-week treatment period per spray.22 The re-
sults showed that FFNS was overall significantly (p 
0.0001) preferred to MFNS.
Relationships between nasal spray attributes and
treatment compliance and adherence were previously
reported.2,5,7,22,24 Results from one study showed that
“aftertaste” was the attribute patients indicated would
be most likely to affect adherence to treatment; how-
ever, “taste,” “run down the throat,” “run out of the
nose,” “smell,” and “feel of the spray” were also pro-
posed as likely to affect adherence.5 Results from a
survey carried out in 2006 showed that the majority of
patients (61%) who stopped taking a nasal allergy
medication did so because of a characteristic of the
medication and not because of a change in their con-
dition.25
A strength of the current study was that it was
conducted at different sites, in different parts of the
world, with a view to representing the global use of
these treatments. Ethnic differences in nasal physiol-
ogy have been suggested to impact nasal spray depo-
sition.26 However, we did not stratify patients for this
potential difference in this study. A potential study
limitation was that this was a 1-day study, so it is
possible that preferences may change over time. In
addition, the treatment in this study was administered
by a trained health care professional with the patient
blindfolded to maintain the blind study. However, reg-
ular clinical practice would be for the patient to self-
administer the spray.
CONCLUSION
In this study we showed that, overall and based on
the individual attributes, patients with allergic rhinitis
preferred FFNS to MFNS. Greater preference may im-
prove patient adherence and thereby improve symp-
tom management of patient’s allergic rhinitis.
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